Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -864.28% is 30% above its 4-year average of -1226.03%, near the high end of its 4-year range (-11566.23%–-244.05%).
31.87% below its 12-month average of -655.42%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -244.05%.
EBITDA MARGIN
-864.28%
EBITDA MARGIN AVG TTM
-655.42%
EBITDA MARGIN AVG 3Y
-1082.52%
EBITDA MARGIN AVG 5Y
-1226.03%
EBITDA MARGIN AVG 10Y
-837.07%
EBITDA MARGIN AVG 15Y
-592.51%
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-31.87%
CURRENT VS 3Y AVG
+20.16%
CURRENT VS 5Y AVG
+29.51%
CURRENT VS 10Y AVG
-3.25%
CURRENT VS 15Y AVG
-45.87%
CURRENT VS 20Y AVG
N/A
Agios Pharmaceuticals, Inc.
Market Cap
$1.90B
EBITDA Margin
-864.28%
TTM Avg
-655.42%
3Y Avg
-1082.52%
5Y Avg
-1226.03%
Market Cap
$1.91B
EBITDA Margin
-13.52%
TTM Avg
-19.53%
3Y Avg
-24.36%
5Y Avg
-23.78%
Market Cap
$1.89B
EBITDA Margin
3.75%
TTM Avg
2.81%
3Y Avg
-0.66%
5Y Avg
-2.07%
Market Cap
$1.88B
EBITDA Margin
-76.84%
TTM Avg
-120.93%
3Y Avg
-91.54%
5Y Avg
-268.52%
Market Cap
$1.88B
EBITDA Margin
-3042.18%
TTM Avg
-3200.65%
3Y Avg
-2392.49%
5Y Avg
-2392.49%
Market Cap
$1.87B
EBITDA Margin
-157.11%
TTM Avg
-157.28%
3Y Avg
-157.28%
5Y Avg
-157.28%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Agios Pharmaceuticals, Inc. (AGIO) | $1.90B | -864.28% | -655.42% | -1082.52% | -1226.03% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | -13.52% | -19.53% | -24.36% | -23.78% |
| BioLife Solutions, Inc. (BLFS)vs › | $1.89B | 3.75% | 2.81% | -0.66% | -2.07% |
| Trevi Therapeutics, Inc. (TRVI)vs › | $1.89B | N/A | N/A | N/A | N/A |
| Zymeworks Inc. (ZYME)vs › | $1.88B | -76.84% | -120.93% | -91.54% | -268.52% |
| Immunome, Inc. (IMNM)vs › | $1.88B | -3042.18% | -3200.65% | -2392.49% | -2392.49% |
| AxoGen, Inc. (AXGN)vs › | $1.94B | 0.15% | 1.29% | -6.34% | -9.86% |
| Palvella Therapeutics, Inc. (PVLA)vs › | $1.87B | -157.11% | -157.28% | -157.28% | -157.28% |
| Mineralys Therapeutics, Inc. (MLYS)vs › | $1.94B | N/A | N/A | N/A | N/A |
| Vir Biotechnology, Inc. (VIR)vs › | $1.96B | -665.65% | -718.65% | -539.20% | -425.23% |
Gross Margin
78.7%
EBITDA Margin
-864.3%
Operating Margin
-873.9%
Net Margin
-418.2%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -244.05% |
| 2026-03-31 | -523.77% |
| 2025-12-31 | -602.55% |
| 2025-09-30 | -896.70% |
| 2025-06-30 | -1010.01% |
| 2025-03-31 | -1207.32% |
| 2024-12-31 | -1152.56% |
| 2024-09-30 | -1131.93% |
| 2024-06-30 | -1209.80% |
| 2024-03-31 | -1107.88% |
| 2023-12-31 | -1476.47% |
| 2023-09-30 | -1341.72% |
| 2023-06-30 | -1329.53% |
| 2023-03-31 | -1537.08% |
| 2022-12-31 | -2199.42% |
| 2022-09-30 | -2462.91% |
| 2022-06-30 | -1663.67% |
| 2022-03-31 | -11566.23% |
| 2020-12-31 | -203.78% |
| 2020-09-30 | -253.59% |
| 2020-06-30 | -235.05% |
| 2020-03-31 | -46.75% |
| 2019-12-31 | -293.36% |
| 2019-09-30 | -411.07% |
| 2019-06-30 | -426.47% |
| 2019-03-31 | -315.87% |
| 2018-12-31 | -314.68% |
| 2018-09-30 | -640.64% |
| 2018-06-30 | -176.20% |
| 2018-03-31 | -1053.26% |
| 2017-12-31 | -902.91% |
| 2017-09-30 | -681.48% |
| 2017-06-30 | -731.77% |
| 2017-03-31 | -622.92% |
| 2016-12-31 | -245.88% |
| 2016-09-30 | -690.88% |
| 2016-06-30 | -790.57% |
| 2016-03-31 | -71.44% |
| 2015-12-31 | -639.31% |
| 2015-09-30 | -719.49% |
| 2015-06-30 | -237.18% |
| 2015-03-31 | -14.11% |
| 2014-12-31 | -180.14% |
| 2014-09-30 | 10.48% |
| 2014-06-30 | -214.04% |
| 2014-03-31 | -142.10% |
| 2013-12-31 | -176.48% |
| 2013-09-30 | -170.58% |
| 2013-06-30 | -130.06% |
| 2013-03-31 | -106.84% |
| 2012-12-31 | -98.28% |
| 2012-09-30 | -76.44% |
| 2012-06-30 | -93.03% |
| 2012-03-31 | -79.77% |
